Personalized Healthcare from Point-to-Point.
The liquid biopsy is performed non-invasively and with a low blood volume to monitor the treatment and to check for recurrence.
LIQUID BIOPSY
Liquid biopsy analysis is an alternative testing procedure in cases where no tumor tissue is available, for example, with irresectable tumor or poor patient conditions. The volume needed for liquid biopsy can depend on the sample type. 3x 10 ml are recommended for blood-based liquid biopsy.
The main target of Liquid biopsy analysis is cell-free DNA (cfDNA) which is released into the bloodstream by necrotic and apoptotic cells.
Elevated levels of cfDNA have been reported in patients with cancer and other types of diseases. The circulating cfDNA is released from both normal and tumor cells. The fraction of tumor-derived cfDNA (circulating tumor DNA/ctDNA) differs from patient to patient, depending on tumor entity, tumor stage, tumor burden, and other factors.
Since only a fraction of circulating DNA is derived from the tumor, highly sensitive methods are required to detect minimal ctDNA concentrations. By very sensitive detection of tumor-specific biomarkers, the analysis of ctDNA can be used as a surrogate marker for treatment response during medical follow-up.
Due to an increase number of tumor therapies available or currently tested in clinical trials targeting specific mutations. Thus, identifying genetic mutations or affected cellular pathways is an essential factor for personalizing the patient’s treatment and finding new treatment options.
01
Coverage
02
Delivery
03
Storage
High coverage: 50,000 – 100,000x raw coverage.
Processing time: 3- 4 weeks from sample receipt.
The sequencing data will be available for download
from our server. Upon request, data can also be delivered via external hard drive.
We will report all relevant findings in a medical report, including a list of all identified clinically relevant variants which are clearly annotated with gene name, functional category of the mutation, transcript-ID, allele frequency, and effect on protein function. Each single medical report is prepared and discussed by an interdisciplinary team of scientists and physicians to guarantee highest quality.
Liquid biopsy enables the detection of variants with potential therapeutic relevance in patients where tumor is inaccessible, allowing tumor characterization and disease monitoring.